N/A
N=102
Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus
Atrial Fibrillation
Bottom Line
View on ClinicalTrials.gov: NCT04223505 ↗Enrolled (actual)
102
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Time to Imaging — 28.1; 7.1 hours
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Contrast enhanced ECG-gated cardiac CT (CCT) (Diagnostic_test); Transesophageal Echocardiography (TEE) (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ottawa Heart Institute Research Corporation
- Primary completion
- Nov 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Imaging |
28.1; 7.1 | — |
| SECONDARY Time to Cardioversion |
4.6; 1.7 | — |
Summary
Evaluating contrast enhanced ECG-gated cardiac CT (CCT) as an alternative to transesophageal echocardiography (TEE) to expedite cardioversion of atrial fibrillation (AF), improve patient care and reduce hospital admissions for AF and atrial flutter.
Eligibility Criteria
Inclusion Criteria
- Admitted patients who require LA imaging prior to cardioversion
- Age ≥18 years old
- Able and willing to comply with the study procedures
Exclusion Criteria
- Indication for acute cardioversion (e.g. hemodynamic instability, acute coronary syndrome (ACS), or pulmonary edema)
- Unwillingness or inability to provide informed consent
- Contraindication to Cardiac CT
- Severe renal insufficiency(GFR< 45ml/min)
- Allergy to intravenous contrast agents
- Contraindications to radiation exposure (for example, pregnancy)
- Inability to perform 20-second breath-hold
- Contraindication to TEE
- Unrepaired tracheoesophageal fistula
- Esophageal obstruction or stricture
- Perforated hollow viscus
- Poor airway control
- Severe respiratory depression
- Uncooperative, unsedated patient
Data sourced from ClinicalTrials.gov (NCT04223505). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.